Company: SXTPW
Filing Date: 2025-08-13
Form Type: 10-Q
Source: 0001554855-25-001009
Chunk: 20

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-08-13
Form: 10-Q
Item: Part I, Item 2
Chunk 20
---
The following discussion and analysis is intended as a review of significant factors affecting our financial condition and results of operations for the periods indicated. The discussion should be read in conjunction with our unaudited consolidated condensed financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and the audited financial statements and the other information set forth in certain of our filings with the SEC, including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on March 27, 2025. In addition to historical information, the following Management’s Discussion and Analysis of Financial Condition and Results of Operations contains forward-looking statements that involve risks and uncertainties. Our actual results could differ significantly from those anticipated in these forward-looking statements as a result of certain factors discussed herein and any other periodic reports filed and to be filed with the SEC.

Overview

We are a specialty pharmaceutical company with a goal of using cutting-edge biological science and applied research to further develop and commercialize new therapies for the prevention and treatment of infectious diseases. We have successfully achieved regulatory approval of Arakoda® (“Arakoda”), a malaria preventative treatment that has been on the market since late 2019. Currently, 60P’s pipeline under development covers development programs for vector-borne, fungal, and viral diseases utilizing three of the Company’s future products: (i) new products that contain the Arakoda regimen of Tafenoquine; (ii) new products that contain Tafenoquine; and (iii) Celgosivir and/or botanical extracts from Australian Chestnut Trees.

Business Developments

The following highlights significant business developments in our business during the quarter ended June 30, 2025.

 ●The Company concluded several commercial research studies that collectively suggest that annual incidence of babesiosis is between 25,000 and 380,000 cases, and that the total addressable market for Arakoda for babesiosis may be up to $1.1 billion over the remaining 10-year patent life for the malaria indication.

 ●A new 8-ct bottle format of Arakoda was introduced into the U.S. supply chain. This option will reduce the cost of Arakoda for short-term travelers and is alleviating the temporary shortage of the 16-ct blister pack of Arakoda in regular supply channels.

Liquidity and Capital Resources

As of June 30, 2025, we had cash and cash equivalents of $1,966,930 ($1,